CTNNB1 and neoplasm: Preclinical studies have shown that inhibitors like PRI-724 and SM04690 target the Wnt/β-catenin signaling pathway [53] and anti-angiogenesis agents like Bevacizumab through their effects on tumor vasculature [13], have demonstrated preferential efficacy in CTNNB1-mutated tumors, potentially enhancing treatment outcomes.